P2X7 receptor involvement in COVID-19 disease

Peter Illes

Exploration of Neuroprotective Therapy ›› 2021, Vol. 1 ›› Issue (1) : 7 -9.

PDF (1195KB)
Exploration of Neuroprotective Therapy ›› 2021, Vol. 1 ›› Issue (1) :7 -9. DOI: 10.37349/ent.2021.00002
Letter to the editor
research-article
P2X7 receptor involvement in COVID-19 disease
Author information +
History +
PDF (1195KB)

Keywords

COVID-19 / SARS-CoV-2 / P2X7 receptor / angiotensin-converting enzyme 2 / cytokine storm / central nervous system complications

Cite this article

Download citation ▾
Peter Illes. P2X7 receptor involvement in COVID-19 disease. Exploration of Neuroprotective Therapy, 2021, 1 (1) : 7-9 DOI:10.37349/ent.2021.00002

登录浏览全文

4963

注册一个新账户 忘记密码

References

[1]

Dos Anjos F, Simoes JLB, Assmann CE, Carvalho FB, Bagatini MD. Potential therapeutic role of purinergic receptors in cardiovascular disease mediated by SARS-CoV-2. J Immunol Res. 2016; 2016: 8632048.

[2]

Di Virgilio F, Tang Y, Sarti AC, Rossato M. A rationale for targeting the P2X7 receptor in Coronavirus disease 19. Br J Pharmacol. 2020; 177: 4990-4.

[3]

Illes P, Rubini P, Ulrich H, Zhao Y, Tang Y. Regulation of microglial functions by purinergic mechanisms in the healthy and diseased CNS. Cells. 2020; 9: 5.

[4]

Illes P, Verkhratsky A, Tang Y. Pathological ATPergic signaling in major depression and bipolar disorder. Front Mol Neurosci. 2020; 12: 331.

[5]

Ribeiro DE, Oliveira-Giacomelli A, Glaser T, Arnaud-Sampaio VF, Andrejew R, Dieckmann L, et al. Hyperactivation of P2X7 receptors as a culprit of COVID-19 neuropathology. Mol Psychiatry. 2021; 26: 1044-59.

[6]

Simoes JLB, Bagatini MD. Purinergic signaling of ATP in COVID-19 associated Guillain-Barre syndrome. J Neuroimmune Pharmacol. 2021; 16: 48-58.

PDF (1195KB)

19

Accesses

0

Citation

Detail

Sections
Recommended

/

〈 〉